Local synovial engagement of angiogenic TIE-2 is associated with the development of persistent erosive rheumatoid arthritis in patients with early arthritis

Arthritis and Rheumatism

Volumn 65, Issue 12, 2013, Pages 3073-3083

  Van De Sande, Marleen G H ^a   De Launay, Daphne ^a   De Hair, Maria J H ^a   García, Samuel ^a   Van De Sande, Gijs P M ^a   Wijbrandts, Carla A ^a   Gerlag, Danielle M ^a   Reedquist, Kris A ^a   Tak, Paul P ^a,b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS;

ADULT; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, TIE-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 84889078128     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38128     Document Type: Article

References (49)

1. Klareskog L, Catrina AI, Paget S,. Rheumatoid arthritis. Lancet 2009; 373: 659-72.
2. Michaud K, Wolfe F,. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 885-906.
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
4. Tak PP,. A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 2012; 51: 600-9.
5. Cader MZ, Filer A, Hazlehurst J, de Pablo P, Buckley CD, Raza K,. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011; 70: 949-55.
6. De Hair MJ, Lehmann KA, van de Sande MG, Maijer KI, Gerlag DM, Tak PP,. The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria: is this still the same disease? Arthritis Rheum 2012; 64: 389-93.
7. Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res 2001; 3: 357-61.
8. Szekanecz Z, Besenyei T, Paragh G, Koch AE,. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009; 42: 563-73.
9. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE,. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002; 4: 201-8.
10. Takahara K, Iioka T, Furukawa K, Uchida T, Nakashima M, Tsukazaki T, et al. Autocrine/paracrine role of the angiopoietin-1 and -2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum Pathol 2004; 35: 150-8.
11. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC,. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003; 48: 2461-71.
12. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30: 260-8.
13. Makinde T, Agrawal DK,. Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease. J Cell Mol Med 2008; 12: 810-28.
14. Hashiramoto A, Sakai C, Yoshida K, Tsumiyama K, Miura Y, Shiozawa K, et al. Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt. Arthritis Rheum 2007; 56: 2170-9.
15. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE,. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 299-306.
16. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-9.
17. Krausz S, Garcia S, Ambarus CA, de Launay D, Foster M, Naiman B, et al. Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis. Ann Rheum Dis 2012; 17: 1402-10.
18. Kurosaka D, Hirai K, Nishioka M, Miyamoto Y, Yoshida K, Noda K, et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 1121-8.
19. Knudsen LS, Klarlund M, Skjodt H, Jensen T, Ostergaard M, Jensen KE, et al. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis: relationship to disease activity and radiographic outcome. J Rheumatol 2008; 35: 1277-87.
20. Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, et al. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007; 124: 158-64.
21. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055-64.
22. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
23. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
24. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM,. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
25. Van der Heijde DM,. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5.
26. Gerlag DM, Tak PP,. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol 2009; 23: 221-32.
27. Van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 2011; 70: 423-7.
28. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
29. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995; 38: 1457-65.
30. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP,. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000; 39: 43-9.
31. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010; 184: 2718-28.
32. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005; 7: R784-95.
33. Smeets TJ, Dolhain RJ, Breedveld FC, Tak PP,. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998; 186: 75-81.
34. Tak PP,. A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) 2012; 51: 600-9.
35. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56: 2929-35.
36. Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D, Duray P, Schumacher RH Jr, et al. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res 2000; 2: 145-53.
37. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 2007; 56: 753-64.
38. Goldbach-Mansky R, Suson S, Wesley R, Hack CE, El-Gabalawy HS, Tak PP,. Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann Rheum Dis 2005; 64: 715-21.
39. Van de Sande MG, de Hair MJ, Schuller Y, van de Sande GP, Wijbrandts CA, Dinant HJ, et al. The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. PLoS One 2012; 7: e36668.
40. Thomas M, Augustin HG,. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-37.
41. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC,. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005; 52: 1585-94.
42. Lemieux C, Maliba R, Favier J, Theoret JF, Merhi Y, Sirois MG,. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005; 105: 1523-30.
43. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999; 286: 2511-4.
44. Kruithof E, Baeten D, de Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005; 7: R569-80.
45. Baeten D, Demetter P, Cuvelier C, van den Bosch F, Kruithof E, van Damme N, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59: 945-53.
46. Fraser A, Fearon U, Reece R, Emery P, Veale DJ,. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001; 44: 2024-8.
47. Ambarus CA, Noordenbos T, de Hair MJ, Tak PP, Baeten DL,. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res Ther 2012; 14: R74.
48. Murdoch C, Tazzyman S, Webster S, Lewis CE,. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-11.
49. Jeong BC, Kim HJ, Bae IH, Lee KN, Lee KY, Oh WM, et al. COMP-Ang1, a chimeric form of angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. Bone 2010; 46: 479-86.